Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 20Unknown 4Recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Observational 8Interventional 2

Sponsor

Conditions

Breast Neoplasms 1320Neoplasms 983Carcinoma, Non-Small-Cell Lung 858Prostatic Neoplasms 723Colorectal Neoplasms 662Lung Neoplasms 548Leukemia, Myeloid, Acute 475Neoplasm Metastasis 431Pancreatic Neoplasms 418Carcinoma, Hepatocellular 406Multiple Myeloma 397Ovarian Neoplasms 391Stomach Neoplasms 378Recurrence 365Squamous Cell Carcinoma of Head and Neck 325Melanoma 293Brain Neoplasms 287Uterine Cervical Neoplasms 283Triple Negative Breast Neoplasms 271Head and Neck Neoplasms 263Glioblastoma 263Precursor Cell Lymphoblastic Leukemia-Lymphoma 254Endometrial Neoplasms 233Lymphoma 227Esophageal Neoplasms 222Rectal Neoplasms 221Sarcoma 211Carcinoma, Renal Cell 203Colonic Neoplasms 193Lymphoma, Large B-Cell, Diffuse 191

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Interventional × Lymphangioleiomyomatosis × Clear all
NCT01799538 2026-05-01

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
100 enrolled

Lymphangioleiomyomatosis

NCT06889168 2026-01-21

LAMP-2

Columbia University

Phase 1 Recruiting
20 enrolled

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡